Profile: AMAG Pharmaceuticals Inc (AMAG.OQ)
6 Dec 2013
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. Feraheme is approved for use in the treatment of both dialysis and non-dialysis dependent chronic kidney disease (CKD) patients. The Company’s principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). In December 2011, Feraheme was also granted marketing approval in Canada for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. GastroMARK, which is marketed and sold under the trade name Lumirem outside of the United States, is the Company’s oral contrast agent used for delineating the bowel in magnetic resonance imaging (MRI), and is approved and marketed in the United States, Europe, and other countries through its licensees.
The Company markets and sells Feraheme in both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD. There are two methods used to treat IDA in CKD patients: oral iron supplements and IV iron. Oral iron supplements are often not absorbed well by the gastrointestinal tract and frequently have unpleasant side effects, such as constipation, diarrhea, and cramping, which can cause patients to stop taking their medication. In addition, it can take an extended time for hemoglobin levels to improve the initiation of oral iron treatment.
For IV iron replacement therapy in patients with CKD, the total therapeutic course of iron typically used in clinical practice is 1,000 milligrams, or one gram. Venofer is administered as a slow intravenous injection over 2 to 5 minutes in doses of 100 to 200 milligrams, thus requiring 5 to 10 physician visits to reach a standard one gram therapeutic course. INFeD and Dexferrum are administered as a slow push in 100 milligram doses and also require up to 10 physician visits to receive a standard one gram therapeutic course. Feraheme is administered as a 510 milligram injection.
The Company competes with Fresenius Medical Care North America, American Regent Laboratories, Inc., Sanofi-Aventis U.S. LLC and Watson Pharmaceuticals, Inc.
AMAG Pharmaceuticals Inc
100 Hayden Ave
LEXINGTON MA 02421